The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma (Q36556492)

14 August 2017

1 reference

title

The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma (English)

1 reference

14 August 2017

W I Bensinger

1

1 reference

14 August 2017

publication date

3 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

20

1 reference

14 August 2017

issue

10

1 reference

14 August 2017

page(s)

1683-1689

1 reference

Drug insight: thalidomide as a treatment for multiple myeloma

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

Graft-versus-myeloma effect in two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

1 reference

7 January 2021

Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Mixed hematopoietic chimerism after hematopoietic stem cell allografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Prolonged overall survival with second on-demand autologous transplant in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404333

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404333

1 reference

Dimensions Publication ID

14 August 2017

1043257094

0 references

1 reference